Gamida Cell - Cord Blood Transplant

The NAM Technology Platform

Gamida Cell’s pre-clinical studies have found that the use of nicotinamide, a form of vitamin B3, in the culture medium, inhibits the loss of functionality that usually occurs during the culture process of cells. Pre-clinical studies have also shown that the expanded cell grafts manufactured using NAM technology demonstrate improved functionality following in vivo (in the body) infusion, e.g. migration, homing, and engraftment (durable retention in the target tissues). Based on these results, Gamida Cell is currently testing in clinical trials (in patients) a pipeline of allogeneic (cells sourced not from the patient) products based on the NAM platform to determine their safety and effectiveness as a treatment for hematological malignancies (blood cancers), sickle cell anemia and thalassemia.

NAM technology and all related products are sole assets of Gamida Cell. The products, currently under pre-clinical and clinical development, are protected by a strong patent portfolio worldwide.

To learn more about our products and clinical trials, please fill in:
* Message: